Skip to content
Search

Latest Stories

UK may signal green for emergency ventilator production

British industry expects the government to give the go-ahead to an emergency ventilator production plan on Wednesday (25) that will see a number of firms join forces to tackle the coronavirus outbreak, three sources told.

Airbus, Smiths, Ford and McLaren are among a number of different firms which will be involved in the process, with the idea that some degree of output, whether that is making components or full ventilators, should ideally begin next week, said a source close to the process.


"It will be upscaling, on more of an industrial scale, existing ventilator designs," one of the sources said.

Companies will provide a range of expertise including 3D printing, manufacturing specific parts, assembly and business planning. The government will make an announcement on Wednesday, the sources said.

Britain is trying to boost the number of ventilators available to its publicly funded health service by using some from private hospitals and building more domestically if possible.

The British government declined to comment on the exact timing or details of the ventilator production plan.

The pandemic has forced doctors in some countries to either ration or plan limiting access to critical care beds and ventilators with many nations scrambling to make or buy more.

Ventilators, which cost tens of thousands of dollars, are mechanical breathing devices that can blow air and oxygen into the lungs.

They are crucial for the care of people with lung failure, which can be one of the complications suffered by patients with severe COVID-19, the disease coronavirus causes. But they don’t necessarily save people.

British prime minister Boris Johnson asked businesses to help make the devices over a week ago when he spoke to more than 60 manufacturing firms and organizations with a number of aerospace and automotive companies contacted.

"Businesses can get involved in any part of the process: design, procurement, assembly, testing, and shipping," his Downing Street office said in a statement on March 16.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less